Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAPLON vs ALDOCLOR-150
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
RAPLON (levosimendan) is a calcium sensitizer that increases myocardial contractility by sensitizing troponin C to calcium, and it also opens ATP-sensitive potassium channels, causing vasodilation.
Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.
Short-term treatment of acutely decompensated chronic heart failure (NYHA III-IV) in patients with low cardiac output refractory to standard therapy,Off-label: Management of low cardiac output syndrome after cardiac surgery,Off-label: Treatment of cardiogenic shock
Hypertension
0.2 mg/kg IV bolus over 30 seconds; may repeat once if necessary after 15 minutes.
ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.
Terminal elimination half-life is approximately 1.5-2.5 hours in patients with normal renal function; prolonged in renal impairment (up to 6-8 hours in end-stage renal disease).
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function. In patients with creatinine clearance <30 m L/min, half-life may be prolonged to 15-20 hours, necessitating dose adjustment.
Primarily metabolized by the liver via conjugation to a methyl ester, which is then further conjugated by glutathione-S-transferase. The active metabolite (OR-1896) has a long half-life.
Methyldopa is metabolized primarily via conjugation and decarboxylation; chlorothiazide is not extensively metabolized and is excreted unchanged in urine.
Primarily renal excretion of unchanged drug (approximately 80-90% of administered dose within 24 hours); minor biliary/fecal elimination (less than 10%).
Renal excretion of unchanged drug accounts for approximately 50-60% of the administered dose; hepatic metabolism contributes the remainder, with metabolites excreted via bile and feces. Less than 2% is excreted unchanged in feces.
Approximately 30-40% bound to plasma proteins, primarily albumin.
Approximately 70-80% bound to plasma proteins, primarily albumin.
Volume of distribution is approximately 0.2-0.3 L/kg, indicating distribution primarily into extracellular fluid.
Vd is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid and limited tissue binding.
Intravenous: 100% (only route used clinically). Intramuscular: Not routinely used; bioavailability data limited.
Oral bioavailability is approximately 70-80%; food does not significantly alter absorption.
No dose adjustment required; RAPLON is not significantly renally eliminated.
Contraindicated in patients with GFR <30 m L/min. For GFR 30-50 m L/min, reduce frequency to every other day. For GFR >50 m L/min, no adjustment necessary.
Child-Pugh A and B: no adjustment; Child-Pugh C: use with caution, consider reducing dose by 50% due to prolonged duration.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Reduce dose by 50% or extend dosing interval. Child-Pugh Class C: Use is not recommended due to risk of hepatic encephalopathy and fluid retention.
0.2 mg/kg IV bolus over 30 seconds; maximum single dose 10 mg; may repeat once after 15 minutes.
Not recommended for pediatric use due to lack of safety and efficacy data in patients under 18 years of age.
Use 0.15 mg/kg IV bolus over 30 seconds due to increased sensitivity and risk of prolonged neuromuscular blockade.
Initiate at lower dose (e.g., half tablet) due to increased sensitivity to antihypertensive effects, risk of orthostatic hypotension, and impaired renal function. Monitor blood pressure and electrolytes closely.
None
None.
Hypotension; tachyarrhythmias; renal impairment; electrolyte disturbances (hypokalemia, hypomagnesemia) may increase risk of arrhythmias; monitoring of blood pressure, heart rate, and ECG required; not recommended in severe hepatic impairment.
May cause sedation, dizziness, and orthostatic hypotension. Avoid abrupt discontinuation. Use with caution in patients with impaired renal function, liver disease, or history of depression. Monitor for electrolyte imbalance, especially hypokalemia, due to chlorothiazide component.,Methyldopa may cause positive direct Coombs test, hemolytic anemia, and liver disorders. Discontinue if jaundice or liver abnormalities occur.
Hypersensitivity to levosimendan or any excipient; severe hypotension (systolic BP < 85 mm Hg); severe tachyarrhythmia; significant mechanical obstruction affecting ventricular filling or outflow; history of torsades de pointes; severe renal impairment (Cr Cl < 30 m L/min); severe hepatic impairment.
Hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs.,Active liver disease or previous methyldopa-induced liver disorders.,Anuria or severe renal impairment (creatinine clearance <30 m L/min).
Grapefruit and grapefruit juice may increase the effects and prolong paralysis. Clarithromycin, itraconazole, and other CYP3A4 inhibitors can enhance duration. Avoid high-fat meals shortly before use as they may delay onset.
Avoid excessive potassium-rich foods (bananas, oranges, spinach) unless directed, as thiazide can cause potassium loss; however, monitor for hypokalemia. Limit sodium intake to enhance antihypertensive effect. Methyldopa absorption is not significantly affected by food.
Pregnancy Category C. No adequate human studies. Trimester 1: Risk of fetal malformations cannot be ruled out; animal studies show decreased fetal weight at maternally toxic doses. Trimester 2-3: Potential for fetal respiratory depression or apnea when used near term; avoid during labor.
First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Second and third trimesters: Risk of intrauterine growth restriction (IUGR), oligohydramnios, and renal dysplasia. Neonatal: Folate deficiency, megaloblastic anemia, and potential for methotrexate-like toxicity if used near term.
Not recommended. No human data available on excretion into breast milk. M/P ratio unknown.
Pyrimethamine (component of ALDOCLOR-150) is excreted into breast milk in small amounts; the M/P ratio is not well established. Sulfadoxine (component) is also excreted. Theoretical risk of kernicterus in jaundiced infants due to sulfonamide displacement of bilirubin. Use with caution, especially in preterm or G6PD-deficient infants. The benefits of breastfeeding should outweigh potential risks; alternative antimalarials are preferred.
No dose adjustment required; however, increased clearance in late pregnancy may necessitate higher doses, but clinical significance unknown.
No standard dose adjustment required, but consider increased folic acid supplementation (5 mg daily) to reduce teratogenic risk. Due to increased glomerular filtration rate (GFR) in pregnancy, renal clearance may be enhanced; however, ALDOCLOR-150 is typically used as a single dose and pharmacokinetic data do not support routine dose adjustment. Individualize based on clinical response and toxicity monitoring.
RAPLON (rapacuronium) is a rapid-onset, short-duration nondepolarizing neuromuscular blocker. It produces paralysis within 60-90 seconds and lasts 15-20 minutes. Avoid in patients with significant hepatic or renal impairment. Use with caution in elderly and those with electrolyte imbalances. Reversal with neostigmine is effective but may require higher doses. Monitor for histamine release and bronchospasm, especially in asthmatics.
ALDOCLOR-150 combines chlorothiazide (a thiazide diuretic) and methyldopa (a central alpha-2 agonist). Monitor for hypokalemia and hyponatremia due to thiazide; methyldopa may cause positive Coombs test (hemolytic anemia risk) and hepatotoxicity. Titrate methyldopa slowly to avoid sedation. Use with caution in renal impairment (Cr Cl <30 m L/min reduces thiazide efficacy).
This medication causes complete paralysis, including inability to breathe, so you will be on a breathing machine.,Tell your doctor if you have asthma, liver or kidney disease, or any allergies.,Inform your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.,You may experience temporary muscle weakness after the drug wears off.,Avoid grapefruit and grapefruit juice before and after procedure.,Report any difficulty breathing, rash, or itching immediately.
Take medication exactly as prescribed, usually once or twice daily.,May cause dizziness or drowsiness; avoid driving until effects are known.,Stand up slowly to prevent falls from low blood pressure.,Report unexplained fever, fatigue, or jaundice (signs of liver issues).,Avoid alcohol, which enhances sedative effects.,Do not stop abruptly (risk of rebound hypertension).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAPLON vs ALDOCLOR-150, answered by our medical review team.
RAPLON is a Antihypertensive that works by RAPLON (levosimendan) is a calcium sensitizer that increases myocardial contractility by sensitizing troponin C to calcium, and it also opens ATP-sensitive potassium channels, causing vasodilation.. ALDOCLOR-150 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAPLON and ALDOCLOR-150 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAPLON is: 0.2 mg/kg IV bolus over 30 seconds; may repeat once if necessary after 15 minutes.. The standard adult dose of ALDOCLOR-150 is: ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAPLON and ALDOCLOR-150 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAPLON is classified as Category C. Pregnancy Category C. No adequate human studies. Trimester 1: Risk of fetal malformations cannot be ruled out; animal studies show decreased fetal weight at maternally toxic doses.. ALDOCLOR-150 is classified as Category C. First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.